Results of Annual General Meeting
Released
Released
Announcement PDF
ASX Announcement
Results of Annual General Meeting
24 November 2022 – Race Oncology Limited (Race or the Company) (ASX: RAC) advises
that its Annual General Meeting of Shareholders was held today at 12.00 pm (AEDT).
The resolutions were voted in accordance with the Notice of Annual General Meeting
previously advised to the Australian Securities Exchange, with all resolutions being
passed on a poll.
Resolution 3 (Replacement of Constitution) was passed by a sufficient majority as a
special resolution.
Further information required by section 251AA(2) of the Corporations Act 2001 (Cth) is
attached.
-ENDSAbout Race Oncology (ASX: RAC)
Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug
called Zantrene®.
Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein.
Overexpression of FTO has been shown to be the genetic driver of a diverse range of
cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear
cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.
In breakthrough preclinical research, Race has also discovered that Zantrene protects
from anthracycline-induced heart damage, while in tandem acting with anthracyclines
and proteasome inhibitors to improve their ability to target breast cancer.
The Company also has compelling clinical data for Zantrene as a chemotherapeutic agent
and is in multiple clinical trials in Acute Myeloid Leukaemia (AML).
Race is pursuing outsized commercial returns for shareholders via its ‘Three Pillar’
strategy for the clinical development of Zantrene. Learn more at www.raceoncology.com
Release authorised by:
Media contact:
Phil Lynch, CEO/MD on behalf
Jane Lowe
of the Race Board of Directors
+61 411 117 774
phillip.lynch@raceoncology.com
jane.lowe@irdepartment.com.au
Race Oncology Ltd ABN 61 149 318 749
Registered office: L36, 1 Macquarie Place, Sydney NSW 2000
www.raceoncology.com
Disclosure of Proxy Votes
Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814
Race Oncology Limited
Annual General Meeting
Thursday, 24 November 2022
In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.
Proxy Votes
Resolution
Decided by
Show of
Hands (S)
or Poll (P)
Total Number
of Proxy Votes
exercisable by
proxies validly
appointed
1 Adoption of Remuneration Report
P
17,015,749
2 Re-Election of Director – Dr John
Edward Cullity
P
23,203,783
3 Replacement of Constitution
P
25,595,486
FOR
AGAINST
16,188,081
44,468
95.14%
0.26%
21,459,638
979,805
92.48%
4.22%
24,736,731
59,343
96.64%
0.23%
ABSTAIN
57,637
2,400,946
9,243
Poll Results (if applicable)
PROXY'S
DISCRETION
FOR
AGAINST
783,200
25,330,017
44,468
4.60%
99.82%
0.18%
764,340
44,743,964
1,030,615
3.29%
97.75%
2.25%
799,412
48,091,154
59,343
3.12%
99.88%
0.12%
ABSTAIN
116,502
2,501,397
125,479
Share your feedback
Discover